

## [Chloroquine](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.5. Antiprotozoal medicines](#) [6.5.3. Antimalarial medicines](#) [6.5.3.1. Antimalarial medicines](#) > [Medicines for curative treatment](#)

ATC codes: [P01BA01](#)

EMLc

Indication

Malaria due to Plasmodium vivax ICD11 code: [1F81](#)

INN

Chloroquine

Medicine type

Chemical agent

List type

Core

Additional notes

For use only for the treatment of P. vivax infection

Formulations

**Oral > Liquid:** 50 mg per 5 mL (base)

**Oral > Solid > tablet:** 150 mg (base)

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 1982 ([TRS 685](#))

Changed in 1995 ([TRS 867](#))

Changed in 2003 ([TRS 920](#))

Changed in 2007 ([TRS 946](#))

Changed in 2007 ([TRS 950](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Chloroquine](#)

DrugBank

[Chloroquine](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the deletion of chloroquine 100 mg tablets from the EML and EMLc; - to modify the formulation descriptions to describe strengths in terms of chloroquine base, without reference to the salt.